Gain Therapeutics, Inc. insider trading

Every open-market purchase and sale by Gain Therapeutics, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

No open-market insider trades reported in the last five years.

Does following Gain Therapeutics, Inc.’s insiders pay?

From May 19, 2022 to August 12, 2024, 5 insiders reported 6 open-market purchases and 0 sales not made under a pre-set plan in Gain Therapeutics, Inc.

Gain Therapeutics, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	12 months after their sales	Latest report
Richman Eric I	CHIEF EXECUTIVE OFFICER	2	—	—	—	July 1, 2024
Calabrese Salvatore	CHIEF FINANCIAL OFFICER	1	—	—	—	May 19, 2022
Islam Khalid	Executive Chairman	1	—	—	—	August 12, 2024
Mack Gene	CFO and Interim CEO	1	—	—	—	August 12, 2024
Riley Jeffrey Scott	Director	1	—	—	—	April 1, 2024

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

← Back to Gain Therapeutics, Inc. · Funds · Politicians